Skip to main content
. 2000 Dec;101(4):541–547. doi: 10.1046/j.1365-2567.2000.t01-1-00138.x

Figure 4.

Figure 4

Rejection of the 4-1BBL+ NRS1 tumours requires 4-1BBL and both CD80 and CD86. One hundred micrograms each of control rat immunoglobulin, anti-4-1BBL (TKS-1), anti-CD80 (RM80), or a combination of both anti-CD86 and CD80 mAbs was administered i.p. every other day for 2 weeks after the inoculation with 4-1BB+ NRS1 (5 × 105 cells/mouse). Tumour size was measured. The results are expressed as tumour volume of each mouse. Similar results were obtained in two independent experiments.